- European health regulators warned on Friday against using Gilead
Sciences Inc's and Bristol-Myers Squibb Co's hepatitis C medicines along
with amiodarone, a drug used to regulate the heartbeat of people with
heart rhythm disorders.
The European Medicines Agency
said there is a risk of severe bradycardia, or heart block, when
Gilead's drug Harvoni or a combination of Gilead's Sovaldi and
Bristol-Myers' Daklinza are used in patients who are also taking
agency's committee for medicinal products for human use recommended
that amiodarone only be used in patients taking these hepatitis C
medicines if other anti-arrhythmics cannot be administered.
Labels: sofosbuvir + amiodarone, Warnings